NTRA News and Press, Natera Inc.

2026-07-09 08:15:10 ET Morgan Stanley analyst issues OVERWEIGHT recommendation for NTRA on July 9, 2026 10:58AM ET. The previous analyst recommendation was Overweight. NTRA was trading at $274.39 at issue of the analyst recommendation. The overall analyst consensus : BUY...

Signatera is the first personalized molecular residual disease (MRD) test for solid tumors to receive IVDR certification in the EU Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that Signatera has received certification as a C...

Newly published study shows Signatera MRD-positive patients lived longer with adjuvant chemotherapy, while MRD-negative patients saw no significant benefit First predictive data for overall survival from GALAXY trial in patients with oligo-metastatic CRC in the liver Natera,...

A look at the top 10 most actives in the United States INLIF LIMITED (INLF) rose 42.6% to $0.0666 on volume of 740,893,463 shares Direxion Daily Semiconductor Bear 3X (SOXS) fell 3.9% to $4.0727 on volume of 109,032,437 shares TNL Mediagene (TNMG) rose 98.8% to $0.97 on volume of 103,658,73...

Signatera™ will be used to evaluate molecular response to APG-157 in the neoadjuvant, induction, and adjuvant settings Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and Aveta Biomics, Inc., a clinical-stage immuno-oncology company advanci...

2026-06-26 16:03:12 ET Investment Overview This is my first time covering Natera, Inc. ( NTRA ) for Seeking Alpha - the company's stock reached an all-time high value per share in trading today, is up >60% on a 12-month basis, and is a remarkable >1,900% on a ten-year basi...

2026-06-26 14:20:00 ET I don’t have a thesis about genomics. I have a data set, and this week it started pointing at the same place. ... Read the full article on Seeking Alpha For further details see: The Disinflation Trade Has A New Address: Genomics

Prospera selected as exclusive donor-derived cell-free DNA (dd-cfDNA) monitoring assay for use in Eledon’s planned Phase 3 trial of tegoprubart in kidney transplantation, expected to initiate in late 2026 Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precisi...

A look at the top 10 most actives in the United States Aditxt Inc. (ADTX) fell 77.2% to $0.0095 on volume of 4,419,910,909 shares GD Culture Group Limited (GDC) rose 3.3% to $0.0216 on volume of 1,264,025,355 shares Direxion Daily Semiconductor Bear 3X (SOXS) rose 1.0% to $4.08 on volume of...

2026-06-24 15:15:03 ET from BTIG issued a price target of $275.00 for NTRA on 2026-06-24 17:00:50. The adjusted price target was set to $275.00. At the time of the announcement, NTRA was trading at $260.72. The overall price target consensus is at $258.22 with high price...